On July 21, Unisound (09678.HK) rose 5.09% in regular trading, trading at HKD 72.15/share, with turnover of HKD 43.28 million. The rally was driven by multiple catalysts including the company's formal launch of U2-Med and continued hospital contract signings.

Specifically, Unisound recently released U2-Med, the industry's first professional large language model covering clinical medicine, medical insurance (including commercial insurance), and pharmaceuticals. The model ranked first in both the full-modality LLM and AI agent categories on the authoritative MedBench benchmark. The company also signed AI healthcare construction projects with multiple Class-A tertiary hospitals including Beijing You'an Hospital and Shandong Provincial Hospital, marking the beginning of scalable commercial replication for its medical AI platform.

Additionally, Unisound showcased its U-Model family and three major Agent clusters at WAIC 2026, presenting a complete intelligent agent system spanning foundational models to scenario-level deployment. The stock had previously plunged 41% on July 1 due to lock-up expiry, and the recent concentration of positive catalysts continues to fuel a technical rebound from deeply oversold levels.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)